Educational information only. Not medical advice.
Compare compounds, understand the differences, and explore the original studies behind them.
Research reviewed October 15, 2026. Start with the overview, then explore the evidence and sources.
Stages summarize the study designs available for the identified material in this selection. Human stages require studies in which people received that material; measuring the body’s own peptide or testing a different analogue does not qualify. Controlled studies can measure hormone responses or other biological changes, as well as clinical outcomes. A higher stage can include unsuccessful trials; the adjacent summary explains the findings and limitations.
Multiple reports from one trial count as one study for this classification. The selected-report totals below describe library coverage. Outcome-specific certainty would require a separate assessment of study limitations, consistency, applicability, precision and publication bias.
Semaglutide is a modified, 31-amino-acid version of GLP-1, a gut hormone involved in blood-glucose regulation and appetite.
Tirzepatide is a modified, 39-amino-acid peptide based on GIP, a hormone released in response to nutrients.
FDA-approved semaglutide formulations cover type 2 diabetes, weight management and cardiovascular risk reduction in specified populations. Ozempic injection also covers kidney outcomes in diabetes-associated chronic kidney disease. Wegovy injection has accelerated approval for adults with noncirrhotic MASH, a metabolic fatty-liver disease with inflammation, and moderate-to-advanced scarring. Indications differ between tablets and injections.
FDA-approved tirzepatide formulations cover type 2 diabetes from age ten, long-term weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro also covers cardiovascular risk reduction in adults with type 2 diabetes at high risk.
The categories describe the most advanced study designs selected for this library. Each summary explains what was measured and what remains uncertain.
Multiple controlled human studies
Separate controlled trials established weight loss and fewer cardiovascular events. FLOW found fewer cases of serious kidney deterioration or death from kidney or cardiovascular causes in diabetic kidney disease. In metabolic fatty-liver disease with inflammation (MASH), liver inflammation and scarring improved; follow-up continues. Weight regain followed withdrawal in a selected extension. Oral SOUL recorded numerically fewer combined kidney complications and deaths from kidney or cardiovascular causes than placebo; that difference remained uncertain, while kidney filtration declined more slowly.
Multiple controlled human studies
Large, separate controlled trials found weight loss, fewer sleep-breathing interruptions and fewer worsening-heart-failure events in their defined populations. SURPASS-CVOT found tirzepatide was not unacceptably worse than dulaglutide for cardiovascular events, meeting its noninferiority requirement. Its favorable numerical event difference did not establish superiority. Heart-failure mortality findings were also imprecise.
GLP-1 and GIP are hormones released in response to food. Activating their receptors can increase insulin release when blood glucose is high and influence how much a person eats. Both medicines bind albumin, a blood protein that helps them remain in circulation longer.
Activates the GLP-1 receptor. Its sequence changes and fatty-acid attachment help prolong its action.
Activates both GIP and GLP-1 receptors. It is one modified peptide with activity at both receptors.
SURMOUNT-5 randomly assigned 751 adults with obesity, or overweight with a weight-related complication, who did not have type 2 diabetes to one of the two medicines for 72 weeks. Both were injected under the skin once a week. Participants used the highest trial amount they could tolerate: 10 or 15 mg of tirzepatide, or 1.7 or 2.4 mg of semaglutide. The trial measured the percentage change in body weight; 750 participants received treatment and entered the analyses.
Participants lost an estimated 13.7% of their starting body weight on average by week 72.
Participants lost an estimated 20.2% of their starting body weight on average by week 72, a greater average reduction than with semaglutide at the amounts compared.
SURPASS-2 randomly assigned 1,879 adults whose type 2 diabetes was inadequately controlled by metformin to weekly injections under the skin for 40 weeks. It compared tirzepatide at 5, 10 or 15 mg with semaglutide at 1 mg. The main measurement was HbA1c, which reflects blood glucose over the preceding months.
HbA1c fell by 1.86 percentage points on average after 40 weeks.
HbA1c fell by 2.01–2.30 percentage points on average across the three tirzepatide groups. Each reduction was statistically greater than the reduction with semaglutide in this trial.
An elimination half-life describes how long the blood concentration takes to fall by half during the measured elimination phase. It helps explain persistence, but does not tell us that one medicine is more potent or that oral and injected amounts are interchangeable.
The product label gives an approximate elimination half-life of one week. Absorption differs between tablets and injections.
Zepbound reports approximately 5–6 days in people with overweight or obesity; Mounjaro reports approximately 5 days in people with type 2 diabetes.
Preventing heart attacks, strokes or cardiovascular death requires trials that follow those events. The major randomized trials used different comparison treatments and populations, so they do not directly rank semaglutide against tirzepatide for cardiovascular protection.
SELECT compared semaglutide with placebo in people with cardiovascular disease and overweight or obesity who did not have diabetes.
SURPASS-CVOT compared tirzepatide with dulaglutide in people with type 2 diabetes and cardiovascular disease. A newer study compared routine-care records of tirzepatide and semaglutide users, but differences in who received each medicine could have influenced its findings.
Nausea, vomiting, diarrhea, constipation and abdominal discomfort are common across approved semaglutide products. More serious concerns include pancreatitis, gallbladder disease, dehydration-associated kidney injury and severe gastrointestinal symptoms. Delayed stomach emptying matters around anesthesia because retained stomach contents can enter the lungs. Damage to the retina associated with diabetes, called diabetic retinopathy, requires attention in patients with a history of the condition, especially as glucose control improves. Combining semaglutide with insulin or medicines that stimulate insulin release increases the risk of low blood glucose, called hypoglycemia. These warnings appear in the current Ozempic injection label.
Nausea, diarrhea, vomiting, constipation and abdominal discomfort are common. Important risks include severe gastrointestinal symptoms, dehydration-associated kidney injury, gallbladder disease, pancreatitis, serious allergy, and low blood glucose when combined with insulin or a medicine that stimulates insulin release. The Zepbound label includes the risk of stomach contents entering the lungs around anesthesia and an August 2026 warning about damage to the retina addressing temporary worsening with rapid glucose improvement. The current label does not recommend use in severe gastroparesis, in which the stomach empties very slowly.
These are selected reports; several reports can come from one trial or cohort. Counts describe this library’s coverage.
No sections match this focus. Choose All sections to read the full comparison.
Read how the compounds differ, what direct studies found, and which questions remain open.
BPC-157 has been studied in several animal injury models and a few small human reports. Research on the defined acetylated TB-500 fragment is largely analytical or laboratory work. A small 2026 rat study tested BPC-157 alongside a TB-500-labeled preparation, but the paper did not fully identify that preparation or establish a clear difference between the two compounds.
CJC-1295 with DAC was designed to bind albumin and prolong growth-hormone signaling, and early studies measured its persistence and hormone effects in healthy volunteers. Modified GRF(1–29) shares the modified GHRH core but lacks that extension; most selected reports concern chemical identification, leaving much less human pharmacology to compare.
Direct trials found greater average weight and blood-glucose reductions with tirzepatide at the formulations tested. Receptor biology, available products, approved uses, cardiovascular outcomes and tolerability add context when comparing the two medicines.
Liraglutide and semaglutide activate the same GLP-1 receptor. Direct trials found larger average weight and blood-glucose reductions with semaglutide under the protocols tested. The comparison explains those trials, formulation differences, tolerability and separate cardiovascular evidence.
ACHIEVE-3 directly compared oral orforglipron capsules with oral semaglutide tablets in adults with type 2 diabetes taking metformin. Orforglipron lowered average blood glucose more. More participants reported stomach or intestinal adverse events or stopped treatment because of adverse events, and the average pulse increase was larger with orforglipron. The results concern the trial formulations and strengths; weight-management products need separate context.